超越平均值:骨转移性前列腺癌中α粒子分布与剂量异质性
研究对7例骨转移性去势抵抗性前列腺癌患者在给药24小时后采集活检标本和血液,记录223Ra活性并用micro-CT分析微结构,通过定量放射自显影和组织病理学分割配准及MIRD形式进行剂量计算。结果显示223Ra摄取在宏观和微观尺度上均不均匀,高活性区域集中于骨-组织界面,吸收剂量分布呈空间非均匀性。
要点
- 7例骨转移性去势抵抗性前列腺癌患者给药24小时后活检,223Ra活性分布存在患者间及患者内差异。
- 微观分布分析证实存在低活性组织背景下的局部高活性区域。
- α粒子发射分布集中于骨-组织界面,吸收剂量剖面呈空间非均匀性。
核心结论
- 小尺度放射药物治疗分布的首批患者数据显示223Ra摄取不均匀。
- 剂量估计为改善患者结局提供机会与挑战,是迈向个体化治疗方法和深入理解α粒子放射药物治疗的第一步。
研究设计与样本
- 从7例骨转移性去势抵抗性前列腺癌患者给药24小时后采集活检标本和血液。
- 记录每个样本的223Ra活性,活检标本微结构用micro-CT分析。
- 定量放射自显影和组织病理学经自动化程序分割与配准。
- 按组织隔室进行活性分布分析,并基于MIRD形式进行剂量计算。
主要发现
- 在宏观和微观尺度上揭示患者样本间及样本内的活性分布差异。
- 微观分布分析证实低活性组织背景中存在局部高活性区域。
- 评估了集中于骨-组织界面的异质性α粒子发射分布,并计算了空间非均匀吸收剂量剖面。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
α-particle emitters are emerging as a potent modality for disseminated cancer therapy because of their high linear energy transfer and localized absorbed dose profile. Despite great interest and pharmaceutical development, there is scant information on the distribution of these agents at the scale of the α-particle pathlength. We sought to determine the distribution of clinically approved [223Ra]RaCl2 in bone metastatic castration-resistant prostate cancer at this resolution, for the first time to our knowledge, to inform activity distribution and dose at the near-cell scale. Methods: Biopsy specimens and blood were collected from 7 patients 24 h after administration. 223Ra activity in each sample was recorded, and the microstructure of biopsy specimens was analyzed by micro-CT. Quantitative autoradiography and histopathology were segmented and registered with an automated procedure. Activity distributions by tissue compartment and dosimetry calculations based on the MIRD formalism were performed. Results: We revealed the activity distribution differences across and within patient samples at the macro- and microscopic scales. Microdistribution analysis confirmed localized high-activity regions in a background of low-activity tissue. We evaluated heterogeneous α-particle emission distribution concentrated at bone-tissue interfaces and calculated spatially nonuniform absorbed-dose profiles. Conclusion: Primary patient data of radiopharmaceutical therapy distribution at the small scale revealed that 223Ra uptake is nonuniform. Dose estimates present both opportunities and challenges to enhance patient outcomes and are a first step toward personalized treatment approaches and improved understanding of α-particle radiopharmaceutical therapies.
引用
- Benabdallah N, Lu P, Abou DS, et al. Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer. J Nucl Med. 2024. PMID: 38124163. doi:10.2967/jnumed.123.266571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。